Prevalence of Adverse Drug Reactions among People Living with HIV in Lagos State University Teaching Hospital, Lagos, Nigeria
Main Article Content
Keywords
ADR, PLHIV , HIV , newly enrolled, Adverse Drug Reaction
Abstract
Background: Human Immunodeficiency Virus (HIV) remains a major public health concern in Nigeria, which has been rated as having a high HIV burden globally. Antiretroviral therapy (ART) has significantly improved life expectancy and reduced HIV-related morbidity and mortality. However, ART is associated with adverse drug reactions (ADRs), which can lead to treatment failure, regimen changes, and non-adherence, ultimately affecting patient outcomes.
Methodology: This was a retrospective cohort study of newly initiated people living with HIV (PLHIV) accessing care at the Lagos State University Teaching Hospital (LASUTH), Ikeja. All newly initiated HIV patients receiving antiretroviral therapy (ART) at LASUTH between March 2023 and March 2025 were included. Data collected during the study period were abstracted, and individuals who experienced an adverse drug reaction (ADR) were recorded. Data was analysed using the Statistical Package for the Social Sciences (SPSS) version 27.0. Statistical significance was established at p ≤ 0.5.
Results: Overall, 533 newly initiated into treatment in the study period. Out of the newly initiated (533), a total of 65 reported adverse reactions to the drugs of treatment, which constituted 12.1% prevalence of ADR in the newly initiated. The mean age of all participants was 40.50 ± 11.76 years. All the newly initiated (100%) were on Tenofovir, Lamivudine, and Dolutegravir (TLD) combination. Pruritus is the commonest symptom in both females and males.
Conclusion: The ADR prevalence among the newly enrolled PLHIV is 12% and pruritus is the commonest ADR seen among the newly enrolled.
References
2. Joint United Nations Programme on HIV/AIDS. Country factsheets: Nigeria [Internet]. Geneva: UNAIDS; 2023 [cited 2025 Jul 2]. Available from: https://www.unaids.org/en/regionscountries/countries/nigeria
3. Joint United Nations Programme on HIV/AIDS. Country progress report—Nigeria global AIDS monitoring [Internet]. Geneva: UNAIDS; 2020 [cited 2025 Jul 2]. Available from: https://www.unaids.org/sites/default/files/country/documents/NGA_2020_countryreport.pdf
4. Federal Ministry of Health (Nigeria). Nigeria HIV/AIDS indicator and impact survey (NAIIS): technical report [Internet]. Abuja: Federal Ministry of Health; 2019 [cited 2025 Jul 2]. Available from: https://ciheb.org/media/SOM/Microsites/CIHEB/documents/NAIIS-Report-2018.pdf
5. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.
6. Fernandez-Montero JV, Eugenia E, Barreiro P, Labarga P, Soriano V. Antiretroviral drug-related toxicities: clinical spectrum, prevention, and management. Expert Opin Drug Saf. 2013;12(5):697–707.
7. Vagiri RV, Meyer JC, Godman B, Gous AGS. Relationship between adherence and health-related quality of life among HIV patients in South Africa: findings and implications. J AIDS HIV Res. 2018;10(8):121–32.
8. Liu S, Yuan D, Zhou Y, Fu G, Wang B. Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies. Ann Med. 2023;55(2):2288309.
9. Kandel CE, Walmsley SL. Dolutegravir: a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther. 2015;9:3547–55.
10. Awodele O, Aliu R, Ali I, Oni Y, Adeyeye CM. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria. Pharmacol Res Perspect. 2018;6(5):e00427.
11. Zondi SL, Naidoo P. Reporting and recording of adverse drug reactions of highly active antiretroviral therapy by HIV infected patients and healthcare professionals respectively in the Ethekwini Metropolitan of Kwa-Zulu Natal, South Africa: a cross-sectional and retrospective comparative study. Pan Afr Med J. 2022;42:218.
12. Mukhtar AA, Isaac K, Ian W, Onyema O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (a case report). PAMJ Clin Med. 2022;8(47):33930.
13. Aderemi-Williams RI, Nduaguba SO, Akoji EM, Ogbo PU, Abah IO. Drug therapy problems identified among patients receiving antiretroviral treatment in a HIV clinic: a prospective study in North Central Nigeria. Pan Afr Med J. 2021;40:233.
14. Chauhan NS, Shah SP, Desai MK, Shah A. A safety analysis of different drug regimens used in human immunodeficiency virus-positive patients. Indian J Sex Transm Dis AIDS. 2018;39(2):84–90.
15. de Pádua CM, Braga LP, Pinto Mendicino CC. Adverse reactions to antiretroviral therapy: a prevalent concern. Rev Panam Salud Publica. 2017;41:e84.
16. Lorío M, Colasanti J, Moreira S, Gutierrez G, Quant C. Adverse drug reactions to antiretroviral therapy in HIV-infected patients at the largest public hospital in Nicaragua. J Int Assoc Provid AIDS Care. 2014;13(5):466–70.
17. Oumar AA, Abdoulaye A, Maiga M, Sidibé Y, Cissoko Y, et al. Adverse drug reactions to antiretroviral therapy (ART): prospective study in HIV-infected adults in Sikasso (Mali). J Pharmacovigil. 2017;5:228.
18. World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions – why health professionals need to take action [Internet]. Geneva: WHO; 2002 [cited 2025 Jul 2]. Available from: https://www.who.int/publications/i/item/WHO-EDM-QSM-2002-2
19. National Agency for Food and Drug Administration and Control (NAFDAC). Nigerian guidelines for detecting & reporting of adverse reactions for pharmaceutical products and medical devices. Abuja: NAFDAC; 2024.
20. Fasipe OJ, Akhideno PE, Owhin OS. The observed effect of adverse drug reactions on the length of hospital stay among medical inpatients in a Nigerian University Teaching Hospital. Toxicol Res Appl. 2019;3:1–7.
21. Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol. 2008;74(3):234–7.
22. Abah IO, Ncube NB, Bradley HA, Agbaji OO, Kanki P. Antiretroviral therapy-associated adverse drug reactions and their effects on virologic failure: a retrospective cohort study in Nigeria. Curr HIV Res. 2018;16(6):436.
23. World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens: policy brief [Internet]. Geneva: WHO; 2019 [cited 2025 Jul 2]. Available from: https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15
24. Federal Ministry of Health (Nigeria). National guidelines for HIV prevention, treatment and care [Internet]. Abuja: FMoH; 2020 [cited 2025 Jul 2]. Available from: https://www.differentiatedservicedelivery.org/wp-content/uploads/National-guidelines-Nigeria-2020.pdf
25. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32.
26. Joint United Nations Programme on HIV/AIDS. Global HIV & AIDS statistics—fact sheet [Internet]. Geneva: UNAIDS; 2025 [cited 2025 Jul 2]. Available from: https://www.unaids.org/en/resources/fact-sheet
27. Shet A, Antony J, Arumugam K, Kumar Dodderi S, Rodrigues R, et al. Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India. PLoS One. 2014;9(3):e91028.
28. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance an essential tool [Internet]. Geneva: WHO; 2006 [cited 2012 Feb 10]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf
29. Pearson KC, Kennedy DL. Adverse drug reactions and the Food and Drug Administration. J Pharm Pract. 1989;2:209–13.
30. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Communities. 2004 Nov 28;L-311:67–128. Available from: http://www.ec.europa.eu/health/files/eudralex/vol1/dir_2001_83/2001_83_ec_en.pdf
31. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229–32.
32. Chioma AD, Chukwuma BD, Chinomnso CN. Prevalence and pattern of adverse drug reactions among HIV-infected patients on highly active antiretroviral therapy (HAART) in Imo State, Nigeria: a hospital-based survey. J Drug Deliv Ther. 2019;9(6-s):5–11.
33. Olusegun IS, Okonkwo P, Adedayo A, Mattew AC, Chekwube IM, Simeon AS, et al. Adverse drug reactions to HAART and associated risk factors among patients living with HIV/AIDS in Makurdi, North Central Nigeria. J Pharmacol Clin Toxicol. 2023;11(2):1175.
34. Namulindwa A, Wasswa JH, Muyindike W, Tamukong R, Oloro J. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study. AIDS Res Ther. 2022;19(1):18.
35. Abah IO, Dayom WD, Dangiwa DA, Aderemi-Williams R, Anejo-Okopi J, Agbaji OO, et al. Comparative incidence of adverse drug reaction during the first and subsequent year of antiretroviral therapy in a Nigerian HIV infected cohort. Afr Health Sci. 2021;21(3):1027–39.
36. Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, Hamelmann C. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12:7.
37. Ezeuko AY, Nduka SO, Nwofia MC, Ezeuko CC, Ekwunife OI. Antiretroviral adverse drug events reported among adult HIV patients in a Nigerian tertiary hospital: a retrospective study. Magna Sci Adv Res Rev. 2024;11(2):23–31.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.